Q3 FY2026 EarningsQ3 FY26 revenue of $1.5M significantly missed the $5.5M consensus, primarily due to the early stage of the LYMPHIR® commercial rollout. Despite the top-line miss, diluted EPS of -$0.34 beat the -$0.36 expectation, aided by lower-than-anticipated R&D spending. Gross margin of 67.0% trailed the 75.0% consensus, reflecting initial scale-up inefficiencies. While the launch shows momentum with a 31% increase in vial orders, the cash position of $17M remains a critical watchpoint for future operations.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Citius Pharma(CTXR) the Revenue is 1.494 M (--%), Miss estimate;the EBIT is -11.73 M (-33.5%), Miss estimate;the EPS is -0.34 (+57.5%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.01B--
-0.00B--%
EBITMiss expectations
-0.01B33.50%
-0.01B12.05%
-0.00B21.45%
EPSExceed expectations
-0.3457.50%
-0.3655.00%
+0.02002.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf